Amgen and Abgenix Complete Biologics License Application for FDA Approval of Panitumumab Read more about Amgen and Abgenix Complete Biologics License Application for FDA Approval of Panitumumab
FDA Approves Extended Dosing of Aranesp(R) to Treat Chemotherapy-Induced Anemia; Every-Three-Week Dosing Can Provide Added Convenience, Potentially Reducing Number of Clinic Visits and Injections for Anemia Treatment Read more about FDA Approves Extended Dosing of Aranesp(R) to Treat Chemotherapy-Induced Anemia; Every-Three-Week Dosing Can Provide Added Convenience, Potentially Reducing Number of Clinic Visits and Injections for Anemia Treatment
New Phase 2 Data Suggest Treatment of Anemia with Aranesp(R) (Darbepoetin Alfa) May Provide Clinical Benefits in Heart Failure Patients Read more about New Phase 2 Data Suggest Treatment of Anemia with Aranesp(R) (Darbepoetin Alfa) May Provide Clinical Benefits in Heart Failure Patients
Hundreds of Local Residents Participate in Breakaway from Cancer Charity Ride to Benefit The Wellness Community; Bruce Jenner Kicks-off Twenty-Five Mile Ride That Coincides with Stage Six of Amgen Tour of California Read more about Hundreds of Local Residents Participate in Breakaway from Cancer Charity Ride to Benefit The Wellness Community; Bruce Jenner Kicks-off Twenty-Five Mile Ride That Coincides with Stage Six of Amgen Tour of California
Investigational Therapy Denosumab Increased Bone Mineral Density with Twice-Yearly Dosing; One Year Data Published in New England Journal of Medicine Read more about Investigational Therapy Denosumab Increased Bone Mineral Density with Twice-Yearly Dosing; One Year Data Published in New England Journal of Medicine
Amgen Prices $5.0 Billion Convertible Senior Notes; Company to Purchase Approximately $3.0 Billion in Common Stock Read more about Amgen Prices $5.0 Billion Convertible Senior Notes; Company to Purchase Approximately $3.0 Billion in Common Stock
Amgen to Offer $4.0 Billion Convertible Senior Notes; Company to Purchase Approximately $3.0 Billion in Common Stock Read more about Amgen to Offer $4.0 Billion Convertible Senior Notes; Company to Purchase Approximately $3.0 Billion in Common Stock
Amgen and Biovitrum Expand Existing License Agreement for Innovative Treatment of Type 2 Diabetes and Other Metabolic Disorders Read more about Amgen and Biovitrum Expand Existing License Agreement for Innovative Treatment of Type 2 Diabetes and Other Metabolic Disorders
Amgen Continues Manufacturing Expansion with Additional $1 Billion Investment in Puerto Rico Read more about Amgen Continues Manufacturing Expansion with Additional $1 Billion Investment in Puerto Rico
Amgen Announces Put Option for Liquid Yield Option Notes Due 2032 and Zero Coupon Convertible Notes Due 2032 Read more about Amgen Announces Put Option for Liquid Yield Option Notes Due 2032 and Zero Coupon Convertible Notes Due 2032
